Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1594383

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1594383

Muscle Relaxants Drug Market by Drug (Facial Muscle Relaxant, Neuromuscular Relaxant, Skeletal Muscle Relaxant), Distribution (Clinics, Drug Stores, Hospitals) - Global Forecast 2025-2030

PUBLISHED:
PAGES: 183 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (2-5 User License)
USD 4249
PDF, Excel & 1 Year Online Access (Site License)
USD 5759
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Muscle Relaxants Drug Market was valued at USD 4.44 billion in 2023, expected to reach USD 4.78 billion in 2024, and is projected to grow at a CAGR of 7.88%, to USD 7.55 billion by 2030.

The muscle relaxants drug market is defined by medications used to relieve muscle spasms, pain, and hyperreflexia, often prescribed for conditions such as back pain, musculoskeletal disorders, and certain neurological disorders. The necessity for these drugs is steeped in their ability to provide immediate relief and improve the quality of life for patients experiencing acute muscular pain and spasticity. Application primarily spans across the healthcare sector, including hospitals, clinics, and retail pharmacies, with muscle relaxants being integrated into treatment regimens for orthopedic and neurological conditions. End-use scope encompasses individual consumers, healthcare providers, and institutional buyers. The market's growth is significantly influenced by the escalating prevalence of musculoskeletal disorders globally, an aging population that is more susceptible to these conditions, and advancements in drug formulations offering improved efficacy. Potential opportunities arise from increasing acceptance of muscle relaxants in emerging markets and the development of innovative, patient-friendly formulations, such as fast-dissolving tablets or topical applications. However, market growth faces challenges in terms of side effects associated with long-term use, stringent regulatory approvals, and the potential for abuse and dependence. The competitive landscape is becoming increasingly saturated, posing additional barriers to entry for new players. Innovations and research in non-addictive formulas and targeted delivery systems, such as transdermal patches or sustained-release capsules, offer notable promise for business growth. Moreover, developing drugs with fewer side effects and integrating AI-driven personalization in prescribing practices could differentiate market offerings. The nature of this market is highly dynamic, with an emphasis on safety and efficacy. Companies can capitalize on emerging trends by focusing on research collaborations with bioengineering firms and proactive regulatory strategizing. Addressing current challenges, like regulatory hurdles and side effects, with advanced biomedical research and patient-centric trials will be pivotal in driving sustained market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 4.44 billion
Estimated Year [2024] USD 4.78 billion
Forecast Year [2030] USD 7.55 billion
CAGR (%) 7.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Muscle Relaxants Drug Market

The Muscle Relaxants Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of lower back pain and other musculoskeletal disorders
    • Surge in surgeries in geriatric population
    • Increasing healthcare expenditure
  • Market Restraints
    • Side effects associated with muscle relaxant drugs such as habituation and respiratory arrest
  • Market Opportunities
    • Growing R&D activities for the development of novel drugs with FDA approvals and strategic collaborations
    • Potential growth in emerging economies
  • Market Challenges
    • Counterfeit drugs in developing countries

Porter's Five Forces: A Strategic Tool for Navigating the Muscle Relaxants Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Muscle Relaxants Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Muscle Relaxants Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Muscle Relaxants Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Muscle Relaxants Drug Market

A detailed market share analysis in the Muscle Relaxants Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Muscle Relaxants Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Muscle Relaxants Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Muscle Relaxants Drug Market

A strategic analysis of the Muscle Relaxants Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Muscle Relaxants Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abbvie Inc., Acorda Therapeutics, Inc., Amneal Pharmaceuticals, Inc., Endo International PLC, Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals, Inc., Johnson & Johnson Services, Inc., Mallinckrodt PLC, Medtronic PLC, Orient Pharma Co., Ltd., Pfizer Inc., SteriMax Inc., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories, LLC.

Market Segmentation & Coverage

This research report categorizes the Muscle Relaxants Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Facial Muscle Relaxant, Neuromuscular Relaxant, and Skeletal Muscle Relaxant.
  • Based on Distribution, market is studied across Clinics, Drug Stores, Hospitals, and Online Stores.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-036C5CF3A8AE

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of lower back pain and other musculoskeletal disorders
      • 5.1.1.2. Surge in surgeries in geriatric population
      • 5.1.1.3. Increasing healthcare expenditure
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with muscle relaxant drugs such as habituation and respiratory arrest
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing R&D activities for the development of novel drugs with FDA approvals and strategic collaborations
      • 5.1.3.2. Potential growth in emerging economies
    • 5.1.4. Challenges
      • 5.1.4.1. Counterfeit drugs in developing countries
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Muscle Relaxants Drug Market, by Drug

  • 6.1. Introduction
  • 6.2. Facial Muscle Relaxant
  • 6.3. Neuromuscular Relaxant
  • 6.4. Skeletal Muscle Relaxant

7. Muscle Relaxants Drug Market, by Distribution

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Drug Stores
  • 7.4. Hospitals
  • 7.5. Online Stores

8. Americas Muscle Relaxants Drug Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Muscle Relaxants Drug Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Muscle Relaxants Drug Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Abbvie Inc.
  • 3. Acorda Therapeutics, Inc.
  • 4. Amneal Pharmaceuticals, Inc.
  • 5. Endo International PLC
  • 6. Hikma Pharmaceuticals PLC
  • 7. Ipsen Biopharmaceuticals, Inc.
  • 8. Johnson & Johnson Services, Inc.
  • 9. Mallinckrodt PLC
  • 10. Medtronic PLC
  • 11. Orient Pharma Co., Ltd.
  • 12. Pfizer Inc.
  • 13. SteriMax Inc.
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. Upsher-Smith Laboratories, LLC
Product Code: MRR-036C5CF3A8AE

LIST OF FIGURES

  • FIGURE 1. MUSCLE RELAXANTS DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. MUSCLE RELAXANTS DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. MUSCLE RELAXANTS DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. MUSCLE RELAXANTS DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MUSCLE RELAXANTS DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MUSCLE RELAXANTS DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY FACIAL MUSCLE RELAXANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY NEUROMUSCULAR RELAXANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY SKELETAL MUSCLE RELAXANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MUSCLE RELAXANTS DRUG MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM MUSCLE RELAXANTS DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 102. MUSCLE RELAXANTS DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. MUSCLE RELAXANTS DRUG MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!